Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

9 Meters Biopharma Inc (NQ: NMTR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 9 Meters Biopharma Inc

< Previous 1 2 3 4 5 Next >
9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- Conference Dates: September 13th-15th - RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
- Conference Dates: September 08th-10th - RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
Via Benzinga
9 Meters Biopharma, EBRIS Foundation Team Up For Larazotide Trial For COVID-19-Associated Complication In Children
9 Meters Biopharma Inc (NASDAQ: NMTR) has collaborated with the European Biomedical Research Institute of Salerno, Italy (EBRIS) to study larazotide for... 
Via Benzinga
9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19
-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"
Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders
9 Meters Biopharma Inc (NASDAQ: NMTR) has acquired global development rights to LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic... 
Via Benzinga
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling... 
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Analyzing 9 Meters Biopharma's Unusual Options Activity
Analyzing 9 Meters Biopharma's Unusual Options Activity Shares of 9 Meters Biopharma (NASDAQ:NMTR) saw some unusual options activity on Thursday. Following the unusual option... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock moved upwards by 78.94% to $3.06 during Thursday's regular session. The current volume of 158.9 million shares is... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Moving iMage Technologies, Inc. (NYSE: MITQ) shares jumped 700% to settle at $24.00 on Thursday. Moving iMage Technologies priced its initial public offering of 4.2... 
Via Benzinga
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
31 Stocks Moving in Thursday's Pre-Market Session
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares rose 46% to $8.41 in pre-market trading after the company reported strong preliminary results for its first quarter... 
Via Benzinga
9 Meters Added to Russell 2000(R) and 3000(R) Indexes
RALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has... 
From 9 Meters Biopharma
Via AccessWire
Topics Derivatives Regulatory Compliance
Exposures COVID-19 Derivatives Legal
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO... 
From 9 Meters Biopharma
Via AccessWire
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high... 
Via Benzinga
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection
- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO,... 
From 9 Meters Biopharma
Via AccessWire
9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
21 Stocks Moving in Monday's Pre-Market Session
Gainers Ocugen, Inc. (NASDAQ: OCGN) shares rose 20.6% to $11.61 in pre-market trading. Ocugen’s COVID-19 vaccine partner, India-based Bharat Biotech International Ltd.,... 
Via Benzinga
Exposures COVID-19
25 Stocks Moving in Friday's Pre-Market Session
Gainers Sypris Solutions, Inc. (NASDAQ: SYPR) shares rose 42% to $3.99 in pre-market trading after the company said its electronics unit has won a contract for deep space program... 
Via Benzinga
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.